TY - JOUR
T1 - Monitoring CD8 T cell responses to NY-ESO-1
T2 - Correlation of humoral and cellular immune responses
AU - Jäger, Elke
AU - Nagata, Yasuhiro
AU - Gnjatic, Sacha
AU - Wada, Hisashi
AU - Stockert, Elisabeth
AU - Karbach, Julia
AU - Dunbar, P. Rod
AU - Lee, Sang Yull
AU - Jungbluth, Achim
AU - Jäger, Dirk
AU - Arand, Michael
AU - Ritter, Gerd
AU - Cerundolo, Vincenzo
AU - Dupont, Bo
AU - Chen, Yao Tseng
AU - Old, Lloyd J.
AU - Knuth, Alexander
PY - 2000/4/25
Y1 - 2000/4/25
N2 - NY-ESO-1, a member of the cancer-testis family of antigens, is expressed in a subset of a broad range of different human tumor types. Patients with advanced NY-ESO-1-expressing tumors frequently develop humoral immunity to NY-ESO-1, and three HLA A2-restricted peptides were defined previously as targets for cytotoxic CD8+ T cells in a melanoma patient with NY-ESO-1 antibody. The objectives of the present study were (i) to develop enzyme- linked immunospot (ELISPOT) and tetramer assays to measure CD8+ T cell responses to NY-ESO-1, (ii) to determine the frequency of CD8+ T cell responses to NY-ESO-1 in a series of HLA-A2 patients with NY-ESO-1 expressing tumors, (ii) to determine the relation between CD8+ T cell and humoral immune responses to NY-ESO-1, and (iv) to compare results of NY-ESO-1 ELISPOT assays performed independently in two laboratories with T cells from the same patients. NY-ESO-1 ELISPOT and tetramer assays with excellent sensitivity, specificity, and reproducibility have been developed and found to correlate with cytotoxicity assays. CD8+ T cell responses to HLA-A2-restricted NY-ESO- 1 peptides were detected in 10 of 11 patients with NY-ESO-1 antibody, but not in patients lacking antibody or in patients with NY-ESO-1-negative tumors. The results of ELISPOT assays were concordant in the two laboratories, providing the basis for standardized monitoring of T cell responses in patients receiving NY-ESO-1 vaccines.
AB - NY-ESO-1, a member of the cancer-testis family of antigens, is expressed in a subset of a broad range of different human tumor types. Patients with advanced NY-ESO-1-expressing tumors frequently develop humoral immunity to NY-ESO-1, and three HLA A2-restricted peptides were defined previously as targets for cytotoxic CD8+ T cells in a melanoma patient with NY-ESO-1 antibody. The objectives of the present study were (i) to develop enzyme- linked immunospot (ELISPOT) and tetramer assays to measure CD8+ T cell responses to NY-ESO-1, (ii) to determine the frequency of CD8+ T cell responses to NY-ESO-1 in a series of HLA-A2 patients with NY-ESO-1 expressing tumors, (ii) to determine the relation between CD8+ T cell and humoral immune responses to NY-ESO-1, and (iv) to compare results of NY-ESO-1 ELISPOT assays performed independently in two laboratories with T cells from the same patients. NY-ESO-1 ELISPOT and tetramer assays with excellent sensitivity, specificity, and reproducibility have been developed and found to correlate with cytotoxicity assays. CD8+ T cell responses to HLA-A2-restricted NY-ESO- 1 peptides were detected in 10 of 11 patients with NY-ESO-1 antibody, but not in patients lacking antibody or in patients with NY-ESO-1-negative tumors. The results of ELISPOT assays were concordant in the two laboratories, providing the basis for standardized monitoring of T cell responses in patients receiving NY-ESO-1 vaccines.
UR - http://www.scopus.com/inward/record.url?scp=0038691976&partnerID=8YFLogxK
U2 - 10.1073/pnas.97.9.4760
DO - 10.1073/pnas.97.9.4760
M3 - Article
C2 - 10781081
AN - SCOPUS:0038691976
SN - 0027-8424
VL - 97
SP - 4760
EP - 4765
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 9
ER -